Psyence Biomedical LTD.: Form 20-F for the period ended Mar 31, 2024
Filed with the SEC on Jul 29, 2024 and accepted by EDGAR at Jul 26, 2024, 21:35 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Net income | 12 months2023-04-01 to 2024-03-31 | −$51.2m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2023-04-01 to 2024-03-31 | −$7.82 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2023-04-01 to 2024-03-31 | −$7.82 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2023-04-01 to 2024-03-31 | −$2.9m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2023-04-01 to 2024-03-31 | $5.7k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2024-03-31 | $733.2k | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2024-03-31 | $1.1m | ifrs-full:CurrentAssets |
| Total assets | At period end2024-03-31 | $1.1m | ifrs-full:Assets |
| Total liabilities | At period end2024-03-31 | $12.1m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2024-03-31 | −$11.0m | ifrs-full:Equity |
| Shares outstanding | At period end2024-03-31 | 13,390,659 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001410578-24-001112. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.